📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

MICA: Optimisation of prolonged normothermic liver machine perfusion and assessment of its feasibility to provide extra-corporeal liver support

Lead Research Organisation: University of Oxford
Department Name: Surgical Sciences

Abstract

Shortage of transplantable livers
Liver transplantation is a life-saving treatment for patients with liver failure. Sadly, 15% of patients on the waiting list either die, or become too unwell for a transplant, due to an organ shortage. Despite this, 2 out of 5 potential deceased donor livers are declined for transplant. Many of these declines are because the donors possess characteristics that make their organs too susceptible to deterioration during preservation. Improved preservation will increase the number of transplantable livers.

How are livers preserved?
The traditional method is on ice. During this period, the organ metabolises without oxygen, generating harmful substances that are released when the liver is implanted into the patient.
Machine perfusion at body-temperature has a number of benefits over ice storage. The machine provides the liver with nutrients and oxygen to enable normal metabolism. This allows the organ to recover during preservation, resulting in less injury on implantation and more transplantable livers.
Current liver perfusion devices are licensed up to 24 hours. Prolonged perfusion up to 7 days seems possible in the laboratory, but remains at the early development stage.

The benefits of prolonged perfusion in transplantation
Prolonged perfusion will improve transplant outcomes and increase organ utilisation. The additional time available will enable improved recipient preparation, planned day-time surgery and wider organ-sharing. It will facilitate more detailed assessment of organ quality to minimise discarding of viable livers, and delivery of treatments to resuscitate injured organs.

Use of prolonged perfusion in liver failure
Beyond transplantation, prolonged perfusion holds promise as a treatment for acute and acute-on-chronic liver failure. These are severe forms of liver injury and many of these patients do not survive. However, the liver possesses the ability to regenerate, meaning that if these patients can be supported temporarily, many will recover.
Whereas patients with kidney failure can be supported with dialysis, an equivalent for liver failure has proven elusive due to the complex roles of the liver. However, livers retain many of these functions during machine perfusion. If a liver can be successfully perfused for enough time to allow liver regeneration, a non-transplantable liver could be used to support patients with liver failure to recovery, or to survive long enough to receive a suitable organ.

Aims of the research
1) Improve machine perfusion of the liver at body temperature to enable prolonged perfusion to 7 days.
2) Assess whether a liver support system, based on prolonged machine perfusion of a liver, is capable of replacing the function of a failing liver.
3) Determine the best method to connect a patient to the liver support system.

How will these be achieved?
I will test three interventions targeted at prolonging machine perfusion:
1) Incorporation of a specialist filter to remove harmful substances from the perfusion blood and correct the salt levels.
2) Addition of a solution to the perfusion blood to rejuvenate old red blood cells.
3) Provision of fish-oil based fats with the nutrition for the liver.
To determine whether a machine-perfused-liver is capable of replacing a failing liver, I will subject the liver to challenges that mirror those that occur in liver failure. Finally, we will compare two connection methods: one in which blood is directly exchanged between the "patient" (in this case, a second machine-perfused liver) and the support system, and a second in which specialist filters prevent cells mixing between the two circulations.

Future Plans
Prolonged perfusion will be combined with work exploring organ assessment and gene therapies during preservation to accelerate their development. The liver support experiments will lead to a study in pigs to determine whether the system is effective in practice.

Technical Summary

Background
Liver preservation by normothermic machine perfusion (LNMP) increases organ utilisation for transplant. Although current devices are licensed for 24-hour perfusion, 7-day perfusion appears experimentally feasible.
Beyond its utility in transplantation, prolonged NMP may enable a perfused liver to provide temporary extra-corporeal liver support through connection to patients with acute and acute-on-chronic liver failure (ALF). As NMP-preserved livers retain a range of liver functions, this system may reduce mortality where others have failed.

Aims
P1: Optimisation of LNMP to support 7-day perfusion.
P2: Assessment of capacity of prolonged LNMP to provide Biological Liver Support (BLS).
P3: Determination of optimal interface between patient and BLS circulations.

Methodology
A porcine model of Donation by Circulatory Death will be used to procure livers for NMP.
P1: 3 interventions will be tested for their potential to prolong LNMP:
a) Incorporation of high molecular weight cut-off dialysis.
b) Red blood cell (RBC) rejuvenation therapy.
c) Omega-3 polyunsaturated fatty acid-enriched nutrition.
P2: The capacity of an NMP-liver to reproduce liver function will be quantified through assessment of lactate, ammonia, ICG clearance and factor V synthesis. The ability of an NMP-liver to remove the damage-associated molecular patterns released by a failing liver will be measured in an ex situ model of the BLS set-up. A healthy NMP-liver ('BLS') will be connected to a second NMP-liver, induced to fail through paracetamol overdose ('patient').
P3: The same model will assess the effect of whole-blood versus plasma-only exchange between the 'patient' and 'BLS' circulations on RBC mixing, immune response and functional capacity.

Future Plans
Prolonged LNMP will improve transplant logistics, viability testing and pre-implantation therapeutic delivery. Parts 2 and 3 will provide proof-of-principle for an efficacy study in a porcine ALF model.

Publications

10 25 50
 
Description Extra-corporeal liver cross-circulation using transgenic porcine livers with human brain-dead research donors 
Organisation University of Pennsylvania
Country United States 
Sector Academic/University 
PI Contribution We developed the system and protocol for extra-corporeal liver cross-circulation in a porcine model of acute liver failure. We then performed isolated normothermic perfusion of transgenic porcine livers with whole human blood to demonstrate immunological compatibility. We then employed the ELC protocol/system to test the feasibility of extra-corporeal liver cross-circultion using transgenic porcine livers with human brain dead research donors in collaboration with University of Pennsylvania (transplant surgery team), Gift of Life (Organ procurement organisation) and eGenesis.
Collaborator Contribution University of Pennsylvania transplant surgery team provided expertise in management of brain-dead research donors, liver transplant surgery and ethical considerations of human brain dead research donors. eGenesis provided the genetically engineered porcine livers and infrastructure for procurement of these livers. Gift of Life (organ procurement organisaiton) identified and provided the infrastructure and expertise to manage donors after brainstem declaration of death.
Impact These data will be presented at the EASL congress 2025. The manuscript is currently in preparation.
Start Year 2023
 
Description University of Oxford - University of Edinburgh 
Organisation University of Edinburgh
Department Royal School of Veterinary Studies
Country United Kingdom 
Sector Academic/University 
PI Contribution Experiment design and undertaking of study of extra-corporeal liver cross-circulation in the treatment of acute liver failure in a large animal model
Collaborator Contribution Veterinary anaesthetic input of study
Impact Study of the effect of extra-corporeal liver cross-circulation in the treatment of a porcine model of acute liver failure. ELC successfully improved the biochemical and clinical hallmarks of acute liver failure in this model. Presented at AASLD, 2023. Multi-disciplinary: transplant surgery/research (University of Oxford) - Veterinary anaesthesia/research (University of Edinburgh).
Start Year 2021
 
Title Extra-corporeal liver cross-circulation device 
Description Extra-corporeal liver cross-circulation (ELC). An auxiliary donor liver is perfused ex-situ on a normothermic machine perfusion (NMP) system. Previous research has demonstrated that livers undergoing ex situ NMP demonstrate a range of physiological liver function (e.g. synthetic, metabolic, detoxification, immunological function). In ELC, the circulation of a patient with acute/acute-on-chronic liver failure is continuously exchanged with the perfusate of the ex situ liver NMP system. The auxiliary liver is thereby able to take on the role of the patient's failing native liver. The intention is to provide temporary extra-corporeal liver support (over a period of days), to bridge patients to recovery or potentially transplantation. This system has been tested in a large animal (pig) model of acute liver failure, in which it demonstrated improvement in the biochemical and clinical hallmarks of acute liver failure. The principle source of funding for the manufacture of the ELC device was OrganOx Ltd. The next step is to translate this system into a phase 1 trial. 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2023
Development Status Under active development/distribution
Impact The device has been tested in a lage animal model of acute liver failure, in which it demonstrated an improvement in the biochemical and clinical hallmarks of acute liver failure.